Citations

Clear

6273 citation(s) found for "To, Andrew".

GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Zhou, Weihua , Zhao, Zitong , Lin, Angelica , Yang, John Z. , Xu, Jie , Wilder-Romans, Kari , Yang, Annabel , Li, Jing , Solanki, Sumeet , Speth, Jennifer M. , Scott, Andrew J. , Wang, L. , Wen, Bo , Andren, Anthony , Zhang, Li , Yao, Yangyang , Peterson, Erik , Korimerla, Navyateja , Werner, Christian K. , Ullrich, Alexander , Liang, Jessica , Jacobson, Janna , O’Brien, Alexandra M., Elaimy, Ameer L. , Ferris, Sean P. , Zhao, Shuang G. , Zhang, Shuqun , Al‐Holou, Wajd N. , Umemura, Yoshie , Morgan, Meredith A. , Lawrence, Theodore S. , Lyssiotis, Costas A. , Peters‐Golden, Marc , Wahl, Daniel , Walker, Natalie , Scott, Andrew J , Wang, Lu , Wen, Bo , Andren, Anthony , Zhang, Li , Kothari, Ayesha U , Yao, Yangyang , Peterson, Erik , Korimerla, Navyateja , Werner, Christian K , Ullrich, Alexander , Liang, Jessica , Jacobson, Janna , Palavalasa, Sravya , O'Brien, Alexandra M , Elaimy, Ameer L , Ferris, Sean P , Zhao, Shuang G , Sarkaria, Jann N , Győrffy, Balázs , Zhang, Shuqun , Al-Holou, Wajd N , Umemura, Yoshie , Morgan, Meredith A , Lawrence, Theodore S , Lyssiotis, Costas A , Peters-Golden, Marc , Shah, Yatrik M , Wahl, Daniel , Kothari, Ayesha U. , Sarkaria, Jann N. , Győrffy, Balázs

Mayo Clinic

Cancer Discovery | October 30, 2023 | Volume: 14 | Issue: 1 | Pages: 158-175

10.1158/2159-8290.cd-23-0437 | PMID 37902550 Get It

ABSTRACT How cell metabolism regulates DNA repair is incompletely understood. Here, we define a GTP-mediated signaling cascade that links metabolism to DNA repair and has significant therapeutic implications. GTP, but not other nucleotides, regulates the activity of Rac1, a guanine nucleotide-binding protein, which promotes the dephosphorylation of serine 323 on Abl-interactor 1 (Abi-1) by protein phosphatase 5 (PP5). Dephosphorylated Abi-1, a protein previously not known to activate DNA repair, promotes nonhomologous end joining. In patients and mouse models of glioblastoma, Rac1 and dephosphorylated Abi-1 mediate DNA repair and resistance to standard-of-care genotoxic treatments. The GTP–Rac1–PP5–Abi-1 signaling axis is not limited to brain cancer, as GTP supplementation promotes DNA repair and Abi-1-S323 dephosphorylation in nonmalignant cells and protects mouse tissues from genotoxic insult. This unexpected ability of GTP to regulate DNA repair independently of deoxynucleotide pools has important implications for normal physiology and cancer treatment. SIGNIFICANCE: A newly described GTP-dependent signaling axis is an unexpected link between nucleotide metabolism and DNA repair. Disrupting this pathway can overcome cancer resistance to genotoxic therapy while augmenting it can mitigate genotoxic injury of normal tissues. This article is featured in Selected Articles from This Issue, p. 5
Solitary Fibrous Tumor of Breast and Axilla: Clinicopathological Profile of Five Tumors With Comparison of Risk Stratification Models
Hoda, Raza S. , Duckworth, Lauren A. , Gilmore, Hannah , Cui, Xiaoyan , Arnam, John S. Van , Zhang, Gloria, Rowe, J. Jordi, Xiao, Huijun , Azzato, Elizabeth M. , Goldblum, John R. , Fritchie, Karen , Downs, Erinn, Fritchie, Karen J , Downs, Erinn P, Hoda, Raza S , McIntire, Patrick J. , Sciallis, Andrew P. , Xiao, Huijun

Mayo Clinic

International Journal of Surgical Pathology | October 30, 2023 | Volume: 32 | Issue: 5 | Pages: 895-907

10.1177/10668969231204957 | PMID 37899729 Get It

Introduction: Solitary fibrous tumor (SFT) is a fibroblastic tumor with malignant potential that is underpinned by a recurrent inv12(q13q13)-derived NAB2::STAT6 fusion. Breast and axilla are uncommon locations for this entity. Methods: Records of two academic institutions were electronically searched for breast and axillary SFTs. Clinical and pathologic data were reviewed. Literature review for breast or axillary SFTs was performed. Present study and previously reported tumors were stratified using five SFT risk models: original and modified Demicco metastatic risk, Salas local recurrence risk, Salas metastatic risk, and Thompson local recurrence risk. Results: Five patients with breast or axillary SFT were identified. Median age was 49 years, and median follow-up (available for four patients) was 82 months. Three patients showed no evidence of disease, and one developed recurrence. Literature review identified 58 patients with breast or axillary SFT. Median age was 54 years, and median follow-up (available for 35 patients) was 24 months. Thirty-one patients showed no evidence of disease, three developed recurrence, and one developed metastasis. Original and modified Demicco models and Thompson model showed the highest sensitivity; original and modified Demicco models and Salas metastatic risk model demonstrated the highest specificity. Kaplan–Meier models were used to assess recurrence-free probability (RFP). Original and modified Demicco models predicted RFP when stratified by “low risk” and “moderate/intermediate and high risk” tumor, though sample size was small. Conclusions: While many SFTs of breast and axilla remain indolent, a subset may develop recurrence and rarely metastasize. The modified Demicco risk model demonstrated optimal performance characteristics.
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Rabin, Karen R. , Chen, Zhiguo , Ji, Lingyun , Kairalla, John A. , Hitzler, Johann , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Reshmi, Shalini C. , Bhojwani, Deepa , Maloney, Kelly W. , Mattano, Leonard A. , Larsen, Eric , Salzer, Wanda L. , Carroll, William L. , Raetz, Elizabeth A. , Loh, Mignon L. , Angiolillo, Anne , Ji, Lingyun , Hitzler, Johann K , Yang, Jun J.J. , Carroll, Andrew J , Wood, Brent L , Roberts, Kathryn G , Mullighan, Charles G , Harvey, Richard , Willman, Cheryl , Gastier‐Foster, Julie M. , Rheingold, Susan R , Maloney, Kelly W , Mattano, Leonard A , Schore, Reuven J , Burke, Michael J , Winick, Naomi Joan , Raetz, Elizabeth A , Loh, Mignon L , Hunger, Stephen P , Rabin, Karen R , Devidas, Meenakshi , Wood, Brent L. , Roberts, Kathryn G. , Mullighan, Charles G. , Harvey, Richard C. , Chen, I‐Ming , Willman, Cheryl L. , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | October 27, 2023 | Volume: 42 | Issue: 2 | Pages: 218-227

10.1200/jco.23.00389 | PMID 37890117 Get It

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We analyzed data for DS (n = 743) and non-DS (n = 20,067) patients age 1-30 years on four B-ALL standard-risk (SR) and high-risk trials. RESULTS Patients with DS exhibited more frequent minimal residual disease (MRD) ≥0.01% at end induction (30.8% v 21.5%; P < .001). This difference persisted at end consolidation only in National Cancer Institute (NCI) high-risk patients (34.0% v 11.7%; P < .0001). Five-year event-free survival (EFS) and overall survival (OS) were significantly poorer for DS versus non-DS patients overall (EFS, 79.2% ± 1.6% v 87.5% ± 0.3%; P < .0001; OS, 86.8% ± 1.4% v 93.6% ± 0.2%; P < .0001), and within NCI SR and high-risk subgroups. Multivariable Cox regression analysis of the DS cohort for risk factors associated with inferior EFS identified age >10 years, white blood count >50 × 103/μL, and end-induction MRD ≥0.01%, but not cytogenetics or CRLF2 overexpression. Patients with DS demonstrated higher 5-year cumulative incidence of relapse (11.5% ± 1.2% v 9.1% ± 0.2%; P = .0008), death in remission (4.9% ± 0.8% v 1.7% ± 0.1%; P < .0001), and induction death (3.4% v 0.8%; P < .0001). Mucositis, infections, and hyperglycemia were significantly more frequent in all patients with DS, while seizures were more frequent in patients with DS on high-risk trials (4.1% v 1.8%; P = .005). CONCLUSION Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Mayo Clinic

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Gräser, Yvonne , Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Leal, Sixto M. , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , Wiederhold, Nathan P. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Ahmed, Sarah A , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Luethy, Paul , Kwon-Chung, Kyung J , Nguyen, M Hong , Pancholi, Preeti , Procop, Gary W , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Roilides, Emmanuel , Wiederhold, Nathan , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2023 | Volume: 61 | Issue: 11 | Pages: No page available

10.1128/jcm.00873-23 | PMID 37882528 Get It

ABSTRACT The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.
Genomic epidemiology reveals the dominance of Hennepin County in the transmission of SARS-CoV-2 in Minnesota from 2020 to 2022
Scotch, Matthew , Lauer, Kimberly P., Wieben, Eric D. , Cherukuri, Yesesri , Cunningham, Julie M. , Klee, Eric W. , Harrington, Jonathan J. , Lau, Julie S., McDonough, Samantha J., Mutawe, Mark M., Rentmeester, Chad E., Schlicher, Nicole R., White, Valerie T., Schneider, Susan K., Vedell, Peter T. , Wang, Xiong , Yao, Joseph D. , Pritt, Bobbi S. , Lauer, Kimberly, Pritt, Bobbi S , Norgan, Andrew P , O’Horo, John C. , Norgan, Andrew P.

Mayo Clinic

mSphere | October 26, 2023 | Volume: 8 | Issue: 6 | Pages: No page available

10.1128/msphere.00232-23 | PMID 37882516 Get It

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an unprecedented impact on human health and highlights the need for genomic epidemiology studies to increase our understanding of virus evolution and spread and to inform policy decisions. We sequenced viral genomes from over 22,000 patient samples tested at Mayo Clinic Laboratories between 2020 and 2022 and used Bayesian phylodynamics to describe county and regional spread in Minnesota. The earliest calculated introduction into Minnesota was to Hennepin County from a domestic source around 22 January 2020; 6 weeks before the first confirmed case in the state. This led to the virus spreading to Northern Minnesota and, eventually, the rest of the state. International introductions were most abundant in Hennepin (home to the Minneapolis/St. Paul International Airport) totaling 45 (out of 107) over the 2-year period. Southern Minnesota counties were most common for domestic introductions, with 19 (out of 64), potentially driven by bordering states such as Iowa and Wisconsin as well as Illinois, which is nearby. Hennepin also was, by far, the most dominant source of in-state transmissions to other Minnesota locations ( n = 772) over the 2-year period. We also analyzed the diversity of the location source of SARS-CoV-2 viruses in each county and noted the timing of state-wide policies as well as trends in clinical cases. Neither the number of clinical cases nor the major policy decisions, such as the end of the lockdown period in 2020 or the end of all restrictions in 2021, appeared to have an impact on virus diversity across each individual county. IMPORTANCE We analyzed over 22,000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes of patient samples tested at Mayo Clinic Laboratories during a 2-year period in the COVID-19 pandemic, which included Alpha, Delta, and Omicron variants of concern to examine the roles and relationships of Minnesota virus transmission. We found that Hennepin County, the most populous county, drove the transmission of SARS-CoV-2 viruses in the state after including the formation of earlier clades including 20A, 20C, and 20G, as well as variants of concern Alpha and Delta. We also found that Hennepin County was the source for most of the county-to-county introductions after an initial predicted introduction with the virus in early 2020 from an international source, while other counties acted as transmission “sinks.” In addition, major policies, such as the end of the lockdown period in 2020 or the end of all restrictions in 2021, did not appear to have an impact on virus diversity across individual counties.
Population pharmacokinetic model of cefepime for critically ill adults: a comparative assessment of eGFR equations
Frazee, Erin N. , Chang, Jack , Mara, Kristin C. , Meade, Laurie A., Paul, Johar , Jannetto, Paul J. , Athreya, Arjun P. , Scheetz, Marc H. , Group, for the BLOOM Study, Frazee, Erin N , Scheetz, Marc H , Mara, Kristin C , Rule, Andrew D. , Group, for the BLOOM Study

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 26, 2023 | Volume: 67 | Issue: 11 | Pages: No page available

10.1128/aac.00810-23 | PMID 37882514 Get It

ABSTRACT Cefepime exhibits highly variable pharmacokinetics in critically ill patients. The purpose of this study was to develop and qualify a population pharmacokinetic model for use in the critically ill and investigate the impact of various estimated glomerular filtration rate (eGFR) equations using creatinine, cystatin C, or both on model parameters. This was a prospective study of critically ill adults hospitalized at an academic medical center treated with intravenous cefepime. Individuals with acute kidney injury or on kidney replacement therapy or extracorporeal membrane oxygenation were excluded. A nonlinear mixed-effects population pharmacokinetic model was developed using data collected from 2018 to 2022. The 120 included individuals contributed 379 serum samples for analysis. A two-compartment pharmacokinetic model with first-order elimination best described the data. The population mean parameters (standard error) in the final model were 7.84 (0.24) L/h for CL1 and 15.6 (1.45) L for V1. Q was fixed at 7.09 L/h and V2 was fixed at 10.6 L, due to low observed interindividual variation in these parameters. The final model included weight as a covariate for volume of distribution and the eGFR cr-cysC (mL/min) as a predictor of drug clearance. In summary, a population pharmacokinetic model for cefepime was created for critically ill adults. The study demonstrated the importance of cystatin C to prediction of cefepime clearance. Cefepime dosing models which use an eGFR equation inclusive of cystatin C are likely to exhibit improved accuracy and precision compared to dosing models which incorporate an eGFR equation with only creatinine.
Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females
Cooper, Isabella D. , Kyriakidou, Yvoni , Edwards, Kurtis , Petagine, Lucy , Seyfried, Thomas N. , Duraj, Tomás , Soto-Mota, Adrián , Scarborough, Andrew, Jacome, Sandra L., Brookler, Kenneth H. , Borgognoni, Valentina, Novaes, Vanusa, Al-Faour, Rima, Elliott, Bradley , Brookler, Kenneth , Elliott, Bradley T

Mayo Clinic

International Journal of Molecular Sciences | October 26, 2023 | Volume: 24 | Issue: 21 | Pages: 15621

10.3390/ijms242115621 | PMID 37958602 Get It

Most studies on ketosis have focused on short-term effects, male athletes, or weight loss. Hereby, we studied the effects of short-term ketosis suppression in healthy women on long-standing ketosis. Ten lean (BMI 20.5 ± 1.4), metabolically healthy, pre-menopausal women (age 32.3 ± 8.9) maintaining nutritional ketosis (NK) for > 1 year (3.9 years ± 2.3) underwent three 21-day phases: nutritional ketosis (NK; P1), suppressed ketosis (SuK; P2), and returned to NK (P3). Adherence to each phase was confirmed with daily capillary D-beta-hydroxybutyrate (BHB) tests (P1 = 1.9 ± 0.7; P2 = 0.1 ± 0.1; and P3 = 1.9 ± 0.6 pmol/L). Ageing biomarkers and anthropometrics were evaluated at the end of each phase. Ketosis suppression significantly increased: insulin, 1.78-fold from 33.60 (± 8.63) to 59.80 (± 14.69) pmol/L (p = 0.0002); IGF1, 1.83-fold from 149.30 (± 32.96) to 273.40 (± 85.66) µg/L (p = 0.0045); glucose, 1.17-fold from 78.6 (± 9.5) to 92.2 (± 10.6) mg/dL (p = 0.0088); respiratory quotient (RQ), 1.09-fold 0.66 (± 0.05) to 0.72 (± 0.06; p = 0.0427); and PAI-1, 13.34 (± 6.85) to 16.69 (± 6.26) ng/mL (p = 0.0428). VEGF, EGF, and monocyte chemotactic protein also significantly increased, indicating a pro-inflammatory shift. Sustained ketosis showed no adverse health effects, and may mitigate hyperinsulinemia without impairing metabolic flexibility in metabolically healthy women.
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab
Ramsower, Colleen , Robetorye, Ryan S. , Mwangi, Raphael , Maurer, Matthew J. , Villa, Diego , McDonnell, Tim, Cohen, Jonathon B. , Clot, Guillem , Bühler, Marco M. , Kulis, Marta , Giné, Eva , Cook, James R. , Hill, Brian T. , Beiske, Klaus , Reichart, Alexander, Hartmann, Sylvia , Rimsza, Lisa M. , Ramsower, Colleen A , Maurer, Matthew , Villa, Diego , Feldman, Andrew, Cohen, Jonathon B , Martin-Subero, Jose Ignacio , Cook, James R , Hill, Brian , Raess, Philipp W , Hartmann, Sylvia , Holte, Harald , Rimsza, Lisa M , Rosenthal, Allison , McDonnell, Tim, Feldman, Andrew L. , Habermann, Thomas M. , Campo, Elı́as , Raess, Philipp W. , Holte, Harald , Scott, David W.

Mayo Clinic

British Journal of Haematology | October 26, 2023 | Volume: 204 | Issue: 1 | Pages: 160-170

10.1111/bjh.19153 | PMID 37881141 Get It

SummaryMantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high‐risk call by a simplified MCL international prognostic index (s‐MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high‐risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s‐MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk‐stratify older MCL patients in future clinical trials.